» Articles » PMID: 10725306

In Vitro Biotransformation of Sildenafil (Viagra): Identification of Human Cytochromes and Potential Drug Interactions

Overview
Specialty Pharmacology
Date 2000 Mar 22
PMID 10725306
Citations 29
Authors
Affiliations
Soon will be listed here.
Abstract

The in vitro biotransformation of sildenafil to its major circulating metabolite, UK-103,320, was studied in human liver microsomes and in microsomes containing heterologously expressed human cytochromes. In human liver microsomes, the mean K(m) (+/-S.E. ) was 14.4 +/- 2.0 microM. A screen of the chemical inhibitors omeprazole (10 microM), quinidine (10 microM), sulfaphenazole (10 microM), and ketoconazole (2.5 microM) only revealed detectable inhibition with ketoconazole. Sildenafil biotransformation (36 microM) was inhibited by increasing concentrations of ketoconazole and ritonavir (IC(50) values less than 0.02 microM), which are established cytochrome P450 (CYP) 3A4 inhibitors. Using microsomes containing cDNA-expressed cytochromes, UK-103,320 formation was found to be mediated by four cytochromes: CYP3A4, -2C9, -2C19, and -2D6. Estimated relative contributions to net intrinsic clearance were 79% for CYP3A4 and 20% for CYP2C9; for CYP2C19 and -2D6, estimated contributions were less than 2%. These results demonstrate that CYP3A4 is the primary cytochrome mediating UK-103,320 formation and that drugs that inhibit CYP3A4 are likely to impair sildenafil biotransformation.

Citing Articles

Clinical Trial Data-Driven Risk Assessment of Drug-Drug Interactions: A Rapid and Accurate Decision-Making Tool.

Yuan T, Bi F, Hu K, Zhu Y, Lin Y, Yang J Clin Pharmacokinet. 2024; 63(8):1147-1165.

PMID: 39102093 DOI: 10.1007/s40262-024-01404-0.


Polyvinyl alcohol-citrate-stabilized silver nanoparticles as an optical sensor for selective colorimetric determination of sildenafil.

Avan A Turk J Chem. 2023; 46(6):2024-2035.

PMID: 37621342 PMC: 10446920. DOI: 10.55730/1300-0527.3499.


Impact of Pomegranate Juice on the Pharmacokinetics of CYP3A4- and CYP2C9-Mediated Drugs Metabolism: A Preclinical and Clinical Review.

Mansoor K, Bardees R, Alkhawaja B, Mallah E, Abuqatouseh L, Schmidt M Molecules. 2023; 28(5).

PMID: 36903363 PMC: 10003857. DOI: 10.3390/molecules28052117.


Predicting disruptions to drug pharmacokinetics and the risk of adverse drug reactions in non-alcoholic steatohepatitis patients.

Marie S, Frost K, Hau R, Martinez-Guerrero L, Izu J, Myers C Acta Pharm Sin B. 2023; 13(1):1-28.

PMID: 36815037 PMC: 9939324. DOI: 10.1016/j.apsb.2022.08.018.


Drug-Drug Interactions in the Management of Patients With Pulmonary Arterial Hypertension.

Wu S, Hoang H, Yang J, Papamatheakis D, Poch D, Alotaibi M Chest. 2022; 162(6):1360-1372.

PMID: 35841932 PMC: 9773230. DOI: 10.1016/j.chest.2022.06.042.